MaxCyte,
Inc.
("MaxCyte" or the "Company")
Exercise of options and PDMR
dealing
ROCKVILLE, MD, September 6, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and
commercialization of next-generation cell therapeutics and to
support innovative, cell-based research, announces that between 3
September 2024 and 4 September 2024, as per a filing lodged with
the U.S. Securities and Exchange Commission, Stanley Erck, a
Non-Executive Director of the
Company, exercised options over 47,689
shares of common stock of $0.01 of the Company ("Common
Stock") ("Exercise") in aggregate. The 47,689 new shares of Common
Stock were issued pursuant to the Company's existing its block
admission facility and were sold by Stanley Erck at a price
range between $3.900 and $4.300 per Common Stock
("Sale"). The sold shares represent approximately 6.9%
of Stanley Erck's total equity and option holdings in the
Company's stock capital, respectively.
Following the Exercise and
Sale, Stanley Erck holds 247,751 shares of Common Stock
representing 0.2% of the issued stock capital of the Company.
Following the Exercise, Stanley Erck holds a further 371,879
options over Common Stock and 21,367 restricted stock
units.
The sales and option exercises were
effected pursuant to a Rule 10b5-1 trading plan adopted by Stanley
Erck on 12 March 2024 relating solely to the sale of shares
acquired from exercise of options that expire on 11 November
2024.
MaxCyte Contacts:
|
US IR
Adviser
Gilmartin
Group
David
Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure
Liberum
Emma Earl /
Freddy Crossley
Corporate
Broking
Rupert
Dearden
|
+44 (0)20 7886 2500
|
|
UK IR
Adviser
ICR
Consilium
Mary-Jane
Elliott
Chris
Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow
Electroporation® technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn
more at maxcyte.com and
follow us on X (formerly Twitter) and LinkedIn.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Stanley Erck
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte, Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Exercise of Options over
common stock
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Exercise Price(s)
|
Volume(s)
|
|
|
|
|
$0.040
|
17,922
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
17,922
|
|
|
|
|
- Price
|
$0.040
|
|
|
|
|
e)
|
Date of the transaction
|
3 September 2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Stanley Erck
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte, Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Sale of common stock
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Exercise Price(s)
|
Volume(s)
|
|
|
|
|
$4.0400
|
1283
|
|
|
|
|
$4.0500
|
867
|
|
|
|
|
$4.0550
|
75
|
|
|
|
|
$4.0600
|
1277
|
|
|
|
|
$4.0650
|
547
|
|
|
|
|
$4.0700
|
2471
|
|
|
|
|
$4.0800
|
2030
|
|
|
|
|
$4.0850
|
525
|
|
|
|
|
$4.0900
|
2100
|
|
|
|
|
$4.0950
|
281
|
|
|
|
|
$4.1000
|
2679
|
|
|
|
|
$4.1100
|
372
|
|
|
|
|
$4.1150
|
82
|
|
|
|
|
$4.1250
|
69
|
|
|
|
|
$4.1300
|
365
|
|
|
|
|
$4.1350
|
250
|
|
|
|
|
$4.1400
|
894
|
|
|
|
|
$4.1450
|
201
|
|
|
|
|
$4.1500
|
100
|
|
|
|
|
$4.1550
|
32
|
|
|
|
|
$4.2100
|
101
|
|
|
|
|
$4.2200
|
200
|
|
|
|
|
$4.2400
|
100
|
|
|
|
|
$4.2500
|
412
|
|
|
|
|
$4.2600
|
100
|
|
|
|
|
$4.2700
|
200
|
|
|
|
|
$4.2800
|
1
|
|
|
|
|
$4.2900
|
200
|
|
|
|
|
$4.3000
|
108
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
17,922
|
|
|
|
|
- Price
|
$4.0978
|
|
|
|
|
e)
|
Date of the transaction
|
3 September 2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Stanley Erck
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte, Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Exercise of Options over
common stock
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Exercise Price(s)
|
Volume(s)
|
|
|
|
|
$0.040
|
29,767
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
29,767
|
|
|
|
|
- Price
|
$0.040
|
|
|
|
|
e)
|
Date of the transaction
|
4 September 2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Stanley Erck
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte, Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Sale of common stock
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Exercise Price(s)
|
Volume(s)
|
|
|
|
|
$3.9000
|
416
|
|
|
|
|
$3.9050
|
445
|
|
|
|
|
$3.9100
|
1060
|
|
|
|
|
$3.9150
|
3925
|
|
|
|
|
$3.9200
|
5733
|
|
|
|
|
$3.9250
|
250
|
|
|
|
|
$3.9300
|
501
|
|
|
|
|
$3.9400
|
2267
|
|
|
|
|
$3.9450
|
400
|
|
|
|
|
$3.9500
|
600
|
|
|
|
|
$3.9550
|
200
|
|
|
|
|
$3.9600
|
500
|
|
|
|
|
$3.9650
|
200
|
|
|
|
|
$3.9700
|
632
|
|
|
|
|
$3.9800
|
1400
|
|
|
|
|
$4.0000
|
415
|
|
|
|
|
$4.0100
|
300
|
|
|
|
|
$4.0200
|
3544
|
|
|
|
|
$4.0300
|
1637
|
|
|
|
|
$4.0350
|
1620
|
|
|
|
|
$4.0400
|
500
|
|
|
|
|
$4.0500
|
3159
|
|
|
|
|
$4.0700
|
63
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
29,767
|
|
|
|
|
- Price
|
$3.9686
|
|
|
|
|
e)
|
Date of the transaction
|
4 September 2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|